Literature DB >> 7507835

Functional analysis of glucocorticoid and insulin response sequences in the rat insulin-like growth factor-binding protein-1 promoter.

R Goswami1, R Lacson, E Yang, R Sam, T Unterman.   

Abstract

Insulin-like growth factor-binding protein-1 (IGFBP-1) is produced by the liver and regulated by glucocorticoids and insulin at the level of gene transcription. To identify DNA sequences mediating the effects of glucocorticoids and insulin on IGFBP-1 promoter activity we created luciferase reporter gene constructs and performed transfection studies in H4IIE hepatoma cells. Initial studies confirmed that the IGFBP-1 promoter is functional when inserted in the correct orientation, but not in the reverse orientation. Dexamethasone (DEX) increased promoter activity 10-fold, and insulin reversed this effect of DEX by 85% at 8 h. The effects of DEX were abolished when constructs were truncated to 89 bases from the RNA cap site, and DNase footprinting with the DNA-binding domain of the human glucocorticoid receptor identified an imperfect palindrome containing two receptor-binding sites separated by three nucleotides typical of a glucocorticoid response element (GRE) at this location. Mutation of either binding site (or half-site) disrupted the effects of DEX, confirming that this sequence functions as a GRE. Two other regions of the promoter also footprinted with the glucocorticoid receptor protein and contained sequences consistent with glucocorticoid receptor-binding sites; however, neither of these footprints contained the full structure expected of a functional GRE, and neither mutation nor deletion of these other sequences altered the effects of DEX on promoter activity. To identify the DNA sequences required for the effects of insulin on glucocorticoid-stimulated promoter activity, we created internal deletions throughout the IGFBP-1 promoter region. Deletion of the 22-basepair (bp) sequence immediately 5' from the GRE disrupted the effect of insulin and appeared to increase basal promoter activity at least 2-fold in each of eight experiments (P < 0.001 vs. intact promoter). This region of the IGFBP-1 promoter contains a 19-bp palindrome (CAAAACAAACTTATTTTG) that overlaps the 5'-end of the GRE and is fully conserved in the human IGFBP-1 promoter. Each half of this palindrome resembles previously identified insulin response sequences, and deletion/mutation analysis suggests that each half may contribute to the effects of insulin on promoter activity. Gel shift studies confirmed that this palindrome binds H4IIE nuclear proteins. In summary, we have identified a GRE in the 5'-promoter region of the rat IGFBP-1 gene approximately 90 bp up-stream from the RNA cap site as well as a contiguous 22-bp region that plays a critical role in mediating the effects of insulin on glucocorticoid-stimulated promoter activity.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7507835     DOI: 10.1210/endo.134.2.7507835

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  16 in total

Review 1.  New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c.

Authors:  Fabienne Foufelle; Pascal Ferré
Journal:  Biochem J       Date:  2002-09-01       Impact factor: 3.857

2.  STAMP, a novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression.

Authors:  Yuanzheng He; S Stoney Simons
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

3.  Insulin and insulin-like growth factor 1 antagonize the stimulation of ob gene expression by dexamethasone in cultured rat adipose tissue.

Authors:  B A Reul; L N Ongemba; A M Pottier; J C Henquin; S M Brichard
Journal:  Biochem J       Date:  1997-06-01       Impact factor: 3.857

4.  USP7 attenuates hepatic gluconeogenesis through modulation of FoxO1 gene promoter occupancy.

Authors:  Jessica A Hall; Mitsuhisa Tabata; Joseph T Rodgers; Pere Puigserver
Journal:  Mol Endocrinol       Date:  2014-04-02

5.  Luman/CREB3 recruitment factor regulates glucocorticoid receptor activity and is essential for prolactin-mediated maternal instinct.

Authors:  Amanda C Martyn; Elena Choleris; Daniel J Gillis; John N Armstrong; Talya R Amor; Adam R R McCluggage; Patricia V Turner; Genqing Liang; Kimberly Cai; Ray Lu
Journal:  Mol Cell Biol       Date:  2012-10-15       Impact factor: 4.272

6.  Hepatocyte nuclear factor-1 acts as an accessory factor to enhance the inhibitory action of insulin on mouse glucose-6-phosphatase gene transcription.

Authors:  R S Streeper; E M Eaton; D H Ebert; S C Chapman; C A Svitek; R M O'Brien
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

7.  Effects of peroral insulin and glucose on circulating insulin-like growth factor-1, its binding proteins and thyroid hormones in neonatal calves.

Authors:  Danijela Kirovski; M Lazarević; Ivona Baricević-Jones; Olgica Nedić; Romana Masnikosa; Judith Anna Nikolie
Journal:  Can J Vet Res       Date:  2008-04       Impact factor: 1.310

8.  Inhibitors of signalling identify differential control processes responsible for selective effects of insulin on the expression of phosphoenolpyruvate carboxykinase and gene 33 in rat H4 hepatoma cells.

Authors:  S H Yang; A J Dickson
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

9.  A Liver-Bone Endocrine Relay by IGFBP1 Promotes Osteoclastogenesis and Mediates FGF21-Induced Bone Resorption.

Authors:  Xunde Wang; Wei Wei; Jing Y Krzeszinski; Yubao Wang; Yihong Wan
Journal:  Cell Metab       Date:  2015-10-08       Impact factor: 27.287

10.  Hepatic nuclear factor 3- and hormone-regulated expression of the phosphoenolpyruvate carboxykinase and insulin-like growth factor-binding protein 1 genes.

Authors:  R M O'Brien; E L Noisin; A Suwanichkul; T Yamasaki; P C Lucas; J C Wang; D R Powell; D K Granner
Journal:  Mol Cell Biol       Date:  1995-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.